Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Mucositis 3Hematologic Neoplasms 3Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Multiple Myeloma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Graft vs Host Disease 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

pegfilgrastim 13Filgrastim 13Cytarabine 5Cyclophosphamide 5pegylated granulocyte colony-stimulating factor 4Etoposide 4Methotrexate 3Doxorubicin 3Docetaxel 3trifluridine tipiracil drug combination 2Vincristine 2Daunorubicin 2Cisplatin 2Amifostine 2trilaciclib 1niraparib 1lintuzumab 1leridistim 1isavuconazole 1fludarabine phosphate 1fish oil triglycerides 1etoposide phosphate 1eravacycline 1eflapegrastim 1angiotensin I (1-7) 1Voriconazole 1Vegetables 1Topotecan 1Thioguanine 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neutropenia × angiotensin I (1-7) × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡